UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------| | | | | For the transition period from ____________ ...

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024 Strong Financial Posit ...

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024Strong Financial Position; Ended the Quarter With $321.6 Million in Cash, Cash Equivalents and Marketable SecuritiesEMERYVILLE, Cal ...

Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapyEMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotech ...

Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101's initial efficacy and safety profile and broad potential in B celldriven neuroinflammatory diseases Key biomarkers indicate potential for KYV-101 to durably modify neuroinflammatory diseases with immune system reset Kyverna to present posters on design and methods for company-sponsored clinical trials in neuroinflammatory diseases EMERYVILLE, Calif., Sept. 18 ...

– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology – Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeutic Areas, Appointed to Board of Directors – Together Strengthen Leadership as Trailblazers of Cell Therapy with Extensive Experience Leading Through Clinical Developm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ________________ | --- | --- | |--------------------------------------------------------------------------------------------------------------- ...

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results • Actively recruiting clinical trials in neurology and rheumatology with KYV-101 • No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101 • Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person Syndrome • Received FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia Gravis • Reported clinical experience with f ...

Actively recruiting clinical trials in neurology and rheumatology with KYV-101 No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101 Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person Syndrome Received FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia Gravis Reported clinical experience with first KYV-101 patient disease-free at 1 year after treatment EMERYVILLE, Calif., Aug. 12, 2024 /PRNewswire/ -- Kyverna T ...

The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option "Stiff-person syndrome has devastating and life-altering effects on patients suffering from this rare autoimmune disease," said Amanda Piquet, M.D., director of the Autoimmune Neurology Program at CU Anschutz Medical Campus, Aurora, CO. "I look forward to the data that will emerge from the KYSA-8 trial as this trial could drastically change the treatment land ...